Last updated on July 2019

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients with Generalized Myasthenia Gravis IND 140,115 STUDY NUMBER: ALXN1210-MG-306


Brief description of study

Primary

To assess the efficacy of ravulizumab compared with placebo in the treatment of gMG based on the improvement in the Myasthenia Gravis-Activities of Daily Living (MG-ADL) profile.

Secondary

To assess the efficacy of ravulizumab compared with placebo in the treatment of gMG based on the improvement in the Quantitative Myasthenia Gravis (QMG) total score.

 

Clinical Study Identifier: TX220311

Find a site near you

Start Over

Baptist Health Lexington Clinical Research Center

1740 Nicholasville Road Lexington, KY United States
  Connect »